
MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma
- Authors:
- Yongjie Zhu
- Zihao Li
- Zuotao Wu
- Ting Zhuo
- Lei Dai
- Guanbiao Liang
- Huajian Peng
- Honglin Lu
- Yongyong Wang
-
Affiliations: Department of Cardio‑Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Thoracic Surgery, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region 545026, P.R. China, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China - Published online on: June 13, 2024 https://doi.org/10.3892/ol.2024.14509
- Article Number: 376
-
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
Zhang W, Zhang R, Zeng Y, Li Y, Chen Y, Zhou J, Zhang Y, Wang A, Zhu J, Liu Z, et al: ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of β-catenin by upregulating the E3 ligase NEDD4L. Cell Death Dis. 12:7552021. View Article : Google Scholar : PubMed/NCBI | |
Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, et al: Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Nat Med. 25:1783–1795. 2019. View Article : Google Scholar : PubMed/NCBI | |
Oudkerk M, Liu S, Heuvelmans MA, Walter JE and Field JK: Lung cancer LDCT screening and mortality reduction-evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 18:135–151. 2021. View Article : Google Scholar : PubMed/NCBI | |
Fang C, Liang Y, Huang Y, Jiang D, Li J, Ma H, Guo L, Jiang W and Feng Y: P3H4 promotes malignant progression of lung adenocarcinoma via interaction with EGFR. Cancers (Basel). 14:32432022. View Article : Google Scholar : PubMed/NCBI | |
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI | |
Pan D, Klare K, Petrovic A, Take A, Walstein K, Singh P, Rondelet A, Bird AW and Musacchio A: CDK-regulated dimerization of M18BP1 on a Mis18 hexamer is necessary for CENP-A loading. Elife. 6:e233522017. View Article : Google Scholar : PubMed/NCBI | |
Fujita Y, Hayashi T, Kiyomitsu T, Toyoda Y, Kokubu A, Obuse C and Yanagida M: Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev Cell. 12:17–30. 2007. View Article : Google Scholar : PubMed/NCBI | |
Nardi IK, Zasadzińska E, Stellfox ME, Knippler CM and Foltz DR: Licensing of centromeric chromatin assembly through the Mis18α-Mis18β heterotetramer. Mol Cell. 61:774–787. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sullivan KF, Hechenberger M and Masri K: Human CENP-A contains a histone H3 related histone fold domain that is required for targeting to the centromere. J Cell Biol. 127:581–592. 1994. View Article : Google Scholar : PubMed/NCBI | |
Liu WT, Wang Y, Zhang J, Ye F, Huang XH, Li B and He QY: A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma. Cancer Lett. 425:43–53. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kim IS, Lee M, Park KC, Jeon Y, Park JH, Hwang EJ, Jeon TI, Ko S, Lee H, Baek SH and Kim KI: Roles of Mis18α in epigenetic regulation of centromeric chromatin and CENP-A loading. Mol Cell. 46:260–273. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sun SY, Hu XT, Yu XF, Zhang YY, Liu XH, Liu YH, Wu SH, Li YY, Cui SX and Qu XJ: Nuclear translocation of ATG5 induces DNA mismatch repair deficiency (MMR-D)/microsatellite instability (MSI) via interacting with Mis18α in colorectal cancer. Br J Pharmacol. 178:2351–2369. 2021. View Article : Google Scholar : PubMed/NCBI | |
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al: Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI | |
Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 5:186ra1662013. View Article : Google Scholar : PubMed/NCBI | |
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 3:e16512008. View Article : Google Scholar : PubMed/NCBI | |
Wei TYW, Hsia JY, Chiu SC, Su LJ, Juan CC, Lee YC, Chen JM, Chou HY, Huang JY, Huang HM and Yu CT: Methylosome protein 50 promotes androgen- and estrogen-independent tumorigenesis. Cell Signal. 26:2940–2950. 2014. View Article : Google Scholar : PubMed/NCBI | |
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor- infiltrating immune cells. Cancer Res. 77:e108–e110. 2017. View Article : Google Scholar : PubMed/NCBI | |
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI | |
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI | |
Therneau T: A package for survival analysis in R. R package version 3.6–4. 2024. | |
Kassambara A, Kosinski M and Biecek P: Survminer: Drawing survival curves using ‘ggplot2’. R package version 0.4.9. 2021. | |
Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI | |
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI | |
Langfelder P and Horvath S: WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI | |
Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: A real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 9 (Suppl 1):S42008. View Article : Google Scholar : PubMed/NCBI | |
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. View Article : Google Scholar : PubMed/NCBI | |
Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI | |
Mayakonda A, Lin DC, Assenov Y, Plass C and Koeffler HP: Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28:1747–1756. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al: Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41((Database Issue)): D955–D961. 2013.PubMed/NCBI | |
Stridfeldt F, Cavallaro S, Hååg P, Lewensohn R, Linnros J, Viktorsson K and Dev A: Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. Talanta. 259:1245532023. View Article : Google Scholar : PubMed/NCBI | |
Zhang K, Zhang L, Mi Y, Tang Y, Ren F, Liu B, Zhang Y and Zheng P: A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration. Cancer Sci. 111:4041–4050. 2020. View Article : Google Scholar : PubMed/NCBI | |
Song YX, Sun JX, Zhao JH, Yang YC, Shi JX, Wu ZH, Chen XW, Gao P, Miao ZF and Wang ZN: Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun. 8:2892017. View Article : Google Scholar : PubMed/NCBI | |
Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
Malhotra J, Malvezzi M, Negri E, La Vecchia C and Boffetta P: Risk factors for lung cancer worldwide. Eur Respir J. 48:889–902. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cucchiara F, Petrini I, Romei C, Crucitta S, Lucchesi M, Valleggi S, Scavone C, Capuano A, De Liperi A, Chella A, et al: Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacol Res. 169:1056432021. View Article : Google Scholar : PubMed/NCBI | |
Wang L, Zhang M, Pan X, Zhao M, Huang L, Hu X, Wang X, Qiao L, Guo Q, Xu W, et al: Integrative serum metabolic fingerprints based multi-modal platforms for lung adenocarcinoma early detection and pulmonary nodule classification. Adv Sci (Weinh). 9:e22037862022. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Shu W, Zhao L and Wan J: Advanced mass spectrometric and spectroscopic methods coupled with machine learning for in vitro diagnosis. VIEW. 4:202200382023. View Article : Google Scholar | |
Liang D, Wang Y and Qian K: Nanozymes: Applications in clinical biomarker detection. Interdiscip Med. 1:e202300202023. View Article : Google Scholar | |
Baumann K: Keeping centromeric identity. Nat Rev Mol Cell Biol. 13:3402012. View Article : Google Scholar : PubMed/NCBI | |
Pussila M, Törönen P, Einarsdottir E, Katayama S, Krjutškov K, Holm L, Kere J, Peltomäki P, Mäkinen MJ, Linden J and Nyström M: Mlh1 deficiency in normal mouse colon mucosa associates with chromosomally unstable colon cancer. Carcinogenesis. 39:788–797. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, et al: Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun. 9:32212018. View Article : Google Scholar : PubMed/NCBI | |
Carroll B and Korolchuk VI: Nutrient sensing, growth and senescence. FEBS J. 285:1948–1958. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kamal MA, Al-Zahrani MH, Khan SH, Al-Subhi HA, Kuerban A, Aslam M, Al-Abbasi FA and Anwar F: Tubulin proteins in cancer resistance: A review. Curr Drug Metab. 21:178–185. 2020. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Zeng C, Yan L, Liao W, Zhen C and Yao J: Prognostic value of holliday junction-recognizing protein and its correlation with immune infiltrates in lung adenocarcinoma. Oncol Lett. 24:2322022. View Article : Google Scholar : PubMed/NCBI | |
Yin Q, Chen W, Zhang C and Wei Z: A convolutional neural network model for survival prediction based on prognosis-related cascaded Wx feature selection. Lab Invest. 102:1064–1074. 2022. View Article : Google Scholar : PubMed/NCBI | |
Wei Y, Ouyang GL, Yao WX, Zhu YJ, Li X, Huang LX, Yang XW and Jiang WJ: Knockdown of HJURP inhibits non-small cell lung cancer cell proliferation, migration, and invasion by repressing Wnt/β-catenin signaling. Eur Rev Med Pharmacol Sci. 23:3847–3856. 2019.PubMed/NCBI | |
Afsharpad M, Nowroozi MR, Mobasheri MB, Ayati M, Nekoohesh L, Saffari M, Zendehdel K and Modarressi MH: Cancer-testis antigens as new candidate diagnostic biomarkers for transitional cell carcinoma of bladder. Pathol Oncol Res. 25:191–199. 2019. View Article : Google Scholar : PubMed/NCBI | |
Naetar N, Hutter S, Dorner D, Dechat T, Korbei B, Gotzmann J, Beug H and Foisner R: LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J Cell Sci. 120:737–747. 2007. View Article : Google Scholar : PubMed/NCBI | |
Abdel-Maksoud MA, Hassan F, Mubarik U, Mubarak A, Farrag MA, Alghamdi S, Atuahene SA, Almekhlafi S and Aufy M: An in-silico approach leads to explore six genes as a molecular signatures of lung adenocarcinoma. Am J Cancer Res. 13:727–757. 2023.PubMed/NCBI | |
Zhou H, Bian T, Qian L, Zhao C, Zhang W, Zheng M, Zhou H, Liu L, Sun H, Li X, et al: Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration. Pathol Res Pract. 228:1536802021. View Article : Google Scholar : PubMed/NCBI | |
Wu Q, Chen YF, Fu J, You QH, Wang SM, Huang X, Feng XJ and Zhang SH: Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell Oncol (Dordr). 37:399–407. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Wang Y, Ren C, Wang H, Zhang Y and Xiu Y: Upregulation of centromere protein K is crucial for lung adenocarcinoma cell viability and invasion. Adv Clin Exp Med. 30:691–699. 2021. View Article : Google Scholar : PubMed/NCBI | |
Lai H, Wen X, Peng Y and Zhang L: Identification of stem cell-related gene markers by comprehensive transcriptome analysis to predict the prognosis and immunotherapy of lung adenocarcinoma. Curr Stem Cell Res Ther. 19:743–754. 2024. View Article : Google Scholar : PubMed/NCBI | |
Monteran L, Zait Y and Erez N: It's all about the base: Stromal cells are central orchestrators of metastasis. Trends Cancer. 10:208–229. 2024. View Article : Google Scholar : PubMed/NCBI | |
Gao D, Fang L, Liu C, Yang M, Yu X, Wang L, Zhang W, Sun C and Zhuang J: Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells. Biomed Pharmacother. 167:1156222023. View Article : Google Scholar : PubMed/NCBI | |
Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D and Rufer N: Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol. 4:1542013. View Article : Google Scholar : PubMed/NCBI | |
Speiser DE, Chijioke O, Schaeuble K and Münz C: CD4+ T cells in cancer. Nat Cancer. 4:317–329. 2023. View Article : Google Scholar : PubMed/NCBI | |
Cardenas MA, Prokhnevska N and Kissick HT: Organized immune cell interactions within tumors sustain a productive T-cell response. Int Immunol. 33:27–37. 2021. View Article : Google Scholar : PubMed/NCBI | |
Laurent V, Guérard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, Zaidi F, Majed B, Garandeau D, Socrier Y, et al: Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 7:102302016. View Article : Google Scholar : PubMed/NCBI | |
Zhu M, Xu W, Wei C, Huang J, Xu J, Zhang Y, Zhao Y, Chen J, Dong S, Liu B and Liang C: CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis. Cell Death Dis. 10:7962019. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL, et al: The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut. 65:1522–1534. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jiang N, Zou C, Zhu Y, Luo Y, Chen L, Lei Y, Tang K, Sun Y, Zhang W, Li S, et al: HIF-1α-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling. Theranostics. 10:2553–2570. 2020. View Article : Google Scholar : PubMed/NCBI | |
Cao Y, Geng J, Wang X, Meng Q, Xu S, Lang Y, Zhou Y, Qi L, Wang Z, Wei Z, et al: RNA-binding motif protein 10 represses tumor progression through the Wnt/β-catenin pathway in lung adenocarcinoma. Int J Biol Sci. 18:124–139. 2022. View Article : Google Scholar : PubMed/NCBI | |
Itakura M, Terashima Y, Shingyoji M, Yokoi S, Ohira M, Kageyama H, Matui Y, Yoshida Y, Ashinuma H, Moriya Y, et al: High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 109:1100–1108. 2013. View Article : Google Scholar : PubMed/NCBI | |
Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L and Nemunaitis J: TMB: A promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 27:841–853. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, et al: Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 33:843–852.e4. 2018. View Article : Google Scholar : PubMed/NCBI | |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al: Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 51:202–206. 2019. View Article : Google Scholar : PubMed/NCBI | |
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al: Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 36:633–641. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018. View Article : Google Scholar : PubMed/NCBI | |
Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI | |
Jardim DL, Goodman A, de Melo Gagliato D and Kurzrock R: The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI | |
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A and Peters S: Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI | |
Yang Y, Adebali O, Wu G, Selby CP, Chiou YY, Rashid N, Hu J, Hogenesch JB and Sancar A: Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. Proc Natl Acad Sci USA. 115:E4777–E4785. 2018.PubMed/NCBI | |
Zhu L and Chen L: Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 24:402019. View Article : Google Scholar : PubMed/NCBI | |
Ahmadi A, Mohammadnejadi E and Razzaghi-Asl N: Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations. Comput Biol Med. 163:1072042023. View Article : Google Scholar : PubMed/NCBI | |
Zou J, Lan H, Li W, Xie S, Tong Z, Song X and Wang C: Comprehensive analysis of circular RNA expression profiles in gefitinib-resistant lung adenocarcinoma patients. Technol Cancer Res Treat. 21:153303382211391672022. View Article : Google Scholar : PubMed/NCBI | |
Zhang Q and Xu K: Advances in the research of autophagy in EGFR-TKI treatment and resistance in lung cancer. Zhongguo Fei Ai Za Zhi. 19:607–614. 2016.(In Chinese). PubMed/NCBI | |
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI | |
Chen C, Wan M, Peng X, Zhang Q and Liu Y: GPR37-centered ceRNA network contributes to metastatic potential in lung adenocarcinoma: Evidence from high-throughput sequencing. Transl Oncol. 39:1018192024. View Article : Google Scholar : PubMed/NCBI | |
Wu X, Sui Z, Zhang H, Wang Y and Yu Z: Integrated analysis of lncRNA-Mediated ceRNA network in lung adenocarcinoma. Front Oncol. 10:5547592020. View Article : Google Scholar : PubMed/NCBI | |
Feng W, Gong H, Wang Y, Zhu G, Xue T, Wang Y and Cui G: circIFT80 functions as a ceRNA of miR-1236-3p to promote colorectal cancer progression. Mol Ther Nucleic Acids. 18:375–387. 2019. View Article : Google Scholar : PubMed/NCBI | |
Rao X, Cao H, Yu Q, Ou X, Deng R and Huang J: NEAT1/MALAT1/XIST/PKD-Hsa-Mir-101-3p-DLGAP5 axis as a novel diagnostic and prognostic biomarker associated with immune cell infiltration in bladder cancer. Front Genet. 13:8925352022. View Article : Google Scholar : PubMed/NCBI | |
Duca RB, Massillo C, Dalton GN, Farré PL, Graña KD, Gardner K and De Siervi A: MiR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis. Am J Cancer Res. 11:2802–2820. 2021.PubMed/NCBI | |
Chen Z, Lin X, Wan Z, Xiao M, Ding C, Wan P, Li Q and Zheng S: High expression of EZH2 mediated by ncRNAs correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma. Genes (Basel). 13:8762022. View Article : Google Scholar : PubMed/NCBI | |
Tao L, Xu C, Shen W, Tan J, Li L, Fan M, Sun D, Lai Y and Cheng H: HIPK3 inhibition by exosomal hsa-miR-101-3p is related to metabolic reprogramming in colorectal cancer. Front Oncol. 11:7583362022. View Article : Google Scholar : PubMed/NCBI | |
Song J, Sun Y, Cao H, Liu Z, Xi L, Dong C, Yang R and Shi Y: A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma. Bioengineered. 12:5932–5949. 2021. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Du C, Zhang L, Wang Y, Zhang Y and Li J: lncRNA GSEC promotes the progression of triple negative breast cancer (TNBC) by targeting the miR-202-5p/AXL axis. Onco Targets Ther. 14:2747–2759. 2021. View Article : Google Scholar : PubMed/NCBI | |
Liu R, Ju C, Zhang F, Tang X, Yan J, Sun J, Lv B, Guo Y, Liang Y, Lv XB and Zhang Z: LncRNA GSEC promotes the proliferation, migration and invasion by sponging miR-588/EIF5A2 axis in osteosarcoma. Biochem Biophys Res Commun. 532:300–307. 2020. View Article : Google Scholar : PubMed/NCBI |